The adjuvant APT trial adopted weekly paclitaxel plus trastusumab and achieved a 3-year iDFS rate up to 98.7% in patients with T ≤ 3 cm, N0/N1mi, HER2 + breast cancer [9]. Here, ERBB2 is linked to breast cancer.